INMB Stock Analysis: Buy, Sell, or Hold?
INMB - INmune Bio Inc. Common stock
$1.86
-0.08 (-4.12%)
▼
5d:
+11.71%
30d:
+53.72%
90d:
+57.63%
HOLD
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 06, 2026
22d
Get Alerted When INMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: INMB is 8.8% above its trading range ($1.71). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: INMB is 8.8% above its trading range ($1.71). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: INMB is currently trading at $1.86, which is considered extended relative to its 30-day fair value range of $1.26 to $1.71.
Technical Outlook: Technically, INMB is in a strong downtrend. The price is approaching resistance at $1.53. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: INMB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+276.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INMB is in a strong downtrend. The price is approaching resistance at $1.53. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: INMB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.00 (+276.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.26 -
$1.71
Company Quality Score
52/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BEARISH: Price extended above range (+8.8% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 276.3% below Wall St target ($7.00)
Trading Range Analysis
30-Day Trading Range
$1.26 -
$1.71
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.20
Resistance Level
$1.54
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.54
Wall Street Target
$7.00
(+276.3%)
Revenue Growth (YoY)
257.1%
Share & Embed Analysis
Last updated: July 14, 2026 3:06 AM ET
Data refreshes hourly during market hours. Next update: 4:06 AM
Data refreshes hourly during market hours. Next update: 4:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
